In the waning days of December, a small group of pro-Palestine activists did what many people around the country were also doing—they went to the mall.
Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback